FELLAShip to Better Health
The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * D
| Condition(s) | High Blood Glucose, High Cholesterol, High Cholesterol/Hyperlipidemia, Blood Sugar; High, Obesity & Overweight, Diabetes Type 2 |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are: * Does participation in the FELLAship program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)? * What factors influence the adoption, delivery, and sustainability of the FELLAship program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcome |
| Who can participate | Inclusion Criteria: * Self-identified Black men * Age 18 or older * LE8 (Life's Essential 8) score (threshold not specified, but implies "less than ideal" CVH) * English speaking * Resides in the Metropolitan Birmingham, Alabama area * No physical activity restrictions imposed by a healthcare provider Exclusion Criteria: * Not identifying as Black and male * Under age 18 * Non-English speakers * Not living in the Birmingham, Alabama metro area * Having a healthcare provider-imposed restriction on physical activity * Ideal CVH (i.e., LE8 (Life's Essential 8) score above inclusion threshold) |
| Ages | 18 Years |
| Sex | Male |
| Lead sponsor | University of Alabama at Birmingham |
| Locations | Birmingham, Alabama, United States |
| Start date | 2026-01-01 |
| NCT ID | NCT07220213 |
| Official listing | https://clinicaltrials.gov/study/NCT07220213 |